Personalised Medicine Strategies – Providing More Clinical Benefit
Current personalised medicine strategies provide limited clinical benefit – how do we do better? Luckily Dr Allan Jordan, the Director of Oncology Drug Discovery at leading CRO Sygnature Discovery, was on hand to explain how. Here's another chance to watch...
6 years agoPersonalised Medicine Strategies – Providing More Clinical Benefit
Current personalised medicine strategies provide limited clinical benefit – how do we do better? Luckily Dr Allan Jordan, the Director of Oncology Drug Discovery at leading CRO Sygnature Discovery, was on hand to explain how. Here's another chance to watch...
6 years ago
Key Challenges in Medicinal Chemistry and Biology
This year Proventa debuted its successful online event format for the first time, providing experts from across the sector with an online forum just as useful and educational as our physical events have always been. During the recent Medicinal Chemistry...
6 years agoKey Challenges in Medicinal Chemistry and Biology
This year Proventa debuted its successful online event format for the first time, providing experts from across the sector with an online forum just as useful and educational as our physical events have always been. During the recent Medicinal Chemistry...
6 years ago
Weekly News Round-up – 17/7/20
In the news this week, despite significant alarms recently that GSK’s belantamab mafodotin could endanger patients’ eyes, the multiple myeloma drug has been approved by expert advisers. In other news, Novartis promises to make no profit from 15 of its COVID...
6 years agoWeekly News Round-up – 17/7/20
In the news this week, despite significant alarms recently that GSK’s belantamab mafodotin could endanger patients’ eyes, the multiple myeloma drug has been approved by expert advisers. In other news, Novartis promises to make no profit from 15 of its COVID...
6 years ago



Weekly News Round-up – 10/7/20
In the news this week, the Trump Administration has made another deal to acquire all initial doses of a potential COVID-19 drug, in this case Regeneron’s REGN-COV2. This follows their acquisition of the first batches of Gilead’s remdesivir last week....
6 years agoWeekly News Round-up – 10/7/20
In the news this week, the Trump Administration has made another deal to acquire all initial doses of a potential COVID-19 drug, in this case Regeneron’s REGN-COV2. This follows their acquisition of the first batches of Gilead’s remdesivir last week....
6 years ago

Clinical Trial Continuity and the Impact of COVID-19
Here's a second chance to catch the fascinating keynote panel discussion lead by Josh Rose, VP GM Virtual Trial Solutions Business, IQVIA and joined by Eli Lilly and Co., EMD Serono/Merck KGaA and Janssen. See how you can prepare for...
6 years agoClinical Trial Continuity and the Impact of COVID-19
Here's a second chance to catch the fascinating keynote panel discussion lead by Josh Rose, VP GM Virtual Trial Solutions Business, IQVIA and joined by Eli Lilly and Co., EMD Serono/Merck KGaA and Janssen. See how you can prepare for...
6 years ago



Weekly News Round-up – 3/7/20
Big news this week, with the U.S. administration buying up remdesivir’s stock for the next three months, ensuring no other country will receive any. In other news, Pfizer and BioNTech’s own covid drug has shown promising results in early trials,...
6 years agoWeekly News Round-up – 3/7/20
Big news this week, with the U.S. administration buying up remdesivir’s stock for the next three months, ensuring no other country will receive any. In other news, Pfizer and BioNTech’s own covid drug has shown promising results in early trials,...
6 years agoInterested?
Reserve your space

